Cargando…
WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea
Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are i...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617849/ https://www.ncbi.nlm.nih.gov/pubmed/28905529 http://dx.doi.org/10.4046/trd.2017.0049 |
_version_ | 1783267052977389568 |
---|---|
author | Jeon, Doosoo |
author_facet | Jeon, Doosoo |
author_sort | Jeon, Doosoo |
collection | PubMed |
description | Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are intended to improve detection rate and treatment outcome for MDR-TB through novel, rapid molecular testing and shorter treatment regimens. Key changes include the introduction of a new, shorter MDR-TB treatment regimen, a new classification of medicines and updated recommendations for the conventional MDR-TB regimen. This paper will review these key changes and discuss the potential issues with regard to the implementation of these guidelines in South Korea. |
format | Online Article Text |
id | pubmed-5617849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Korean Academy of Tuberculosis and Respiratory Diseases |
record_format | MEDLINE/PubMed |
spelling | pubmed-56178492017-10-01 WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea Jeon, Doosoo Tuberc Respir Dis (Seoul) Review Despite progress made in tuberculosis control worldwide, the disease burden and treatment outcome of multidrug-resistant tuberculosis (MDR-TB) patients have remained virtually unchanged. In 2016, the World Health Organization released new guidelines for the management of MDR-TB. The guidelines are intended to improve detection rate and treatment outcome for MDR-TB through novel, rapid molecular testing and shorter treatment regimens. Key changes include the introduction of a new, shorter MDR-TB treatment regimen, a new classification of medicines and updated recommendations for the conventional MDR-TB regimen. This paper will review these key changes and discuss the potential issues with regard to the implementation of these guidelines in South Korea. The Korean Academy of Tuberculosis and Respiratory Diseases 2017-10 2017-09-01 /pmc/articles/PMC5617849/ /pubmed/28905529 http://dx.doi.org/10.4046/trd.2017.0049 Text en Copyright©2017. The Korean Academy of Tuberculosis and Respiratory Diseases http://creativecommons.org/licenses/by-nc/4.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Review Jeon, Doosoo WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea |
title | WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea |
title_full | WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea |
title_fullStr | WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea |
title_full_unstemmed | WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea |
title_short | WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update: Applicability in South Korea |
title_sort | who treatment guidelines for drug-resistant tuberculosis, 2016 update: applicability in south korea |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617849/ https://www.ncbi.nlm.nih.gov/pubmed/28905529 http://dx.doi.org/10.4046/trd.2017.0049 |
work_keys_str_mv | AT jeondoosoo whotreatmentguidelinesfordrugresistanttuberculosis2016updateapplicabilityinsouthkorea |